SpaFinder is followed by Hybrigen , which plans to identify and patent cancer-fighting proteins by improved tracking of chemicalbehavior near the tumor.
Dr. Schneider points out that the drug Dimebon bears some chemical similarity to various antidepressants and anti-psychotic drugs that improve behavior.
Daniel Schultz, the FDA's chief device regulator, says new medical devices don't need the large-scale exhaustive trials of the drug industry because it is easier to predict the behavior of a machine than it is to track the chemical interactions of a new drug in the body.